NOMAD Power Solutions, Inc.(NMAD)

Biotechnology · Boca Raton, FL

$4.27+0.25 (+6.35%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T15:42:56.255Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:42:56.255Z.

Quote observation: 2026-10-06T15:40:30.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 52,776,709
TTM revenue · period ending 2026-06-30: 0

FMP input reference: f372f39edc86e990c580289f142e0fc1828f45467bffd466be8591b91f734aee

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NMAD PS Ratio Metrics

PS RATIO

N/A

NMAD Competitors' PS Ratio

NMAD

NOMAD Power Solutions, Inc.

Current

Market Cap

$52.78M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELOX

Eloxx Pharmaceuticals, Inc.

vs NMAD

Market Cap

$52.61M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DWTX

Dogwood Therapeutics, Inc.

vs NMAD

Market Cap

$52.46M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EXOZ

eXoZymes, Inc.

vs NMAD

Market Cap

$51.98M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMA

ImageneBio Inc

vs NMAD

Market Cap

$53.80M

PS Ratio

N/A

TTM Avg

51.20

3Y Avg

31.27

5Y Avg

27.74

RANI

Rani Therapeutics Holdings, Inc.

vs NMAD

Market Cap

$51.44M

PS Ratio

10.55

TTM Avg

47.77

3Y Avg

38.29

5Y Avg

68.25

APLM

Apollomics, Inc.

vs NMAD

Market Cap

$51.39M

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MBOT

Microbot Medical Inc.

vs NMAD

Market Cap

$51.27M

PS Ratio

148.17

TTM Avg

825.85

3Y Avg

825.85

5Y Avg

825.85

INMB

INmune Bio, Inc.

vs NMAD

Market Cap

$51.04M

PS Ratio

N/A

TTM Avg

1293.91

3Y Avg

1758.59

5Y Avg

3330.34

ALDX

Aldeyra The

vs NMAD

Market Cap

$54.53M

PS Ratio

N/A

TTM Avg

4.74

3Y Avg

4.40

5Y Avg

4.40

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
NOMAD Power Solutions, Inc. (NMAD)	$52.78M	N/A	N/A	N/A	N/A
Eloxx Pharmaceuticals, Inc. (ELOX)vs ›	$52.61M	N/A	N/A	N/A	N/A
Dogwood Therapeutics, Inc. (DWTX)vs ›	$52.46M	N/A	N/A	N/A	N/A
eXoZymes, Inc. (EXOZ)vs ›	$51.98M	N/A	N/A	N/A	N/A
ImageneBio Inc (IMA)vs ›	$53.80M	N/A	51.20	31.27	27.74
Rani Therapeutics Holdings, Inc. (RANI)vs ›	$51.44M	10.55	47.77	38.29	68.25
Apollomics, Inc. (APLM)vs ›	$51.39M	N/A	N/A	N/A	N/A
Microbot Medical Inc. (MBOT)vs ›	$51.27M	148.17	825.85	825.85	825.85
INmune Bio, Inc. (INMB)vs ›	$51.04M	N/A	1293.91	1758.59	3330.34
Aldeyra The (ALDX)vs ›	$54.53M	N/A	4.74	4.40	4.40

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-12-31
Q1 FY2026Period ended 2026-03-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31
Q2 FY2026Period ended 2026-06-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-06-30
TTM revenue	$0

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

NMAD PS Ratio Metrics

NMAD Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics